Expanded Access for KHK2455
Sponsor
Kyowa Kirin, Inc. (Industry)
Overall Status
No longer available
CT.gov ID
NCT04321694
Collaborator
University of New Mexico Cancer Center (Other)
Study Details
Study Description
Brief Summary
This is an expanded access program for eligible participants. This program is designed to provide access to KHK2455 in combination with Mogamulizumab prior to the approval by the local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving this investigational therapy based on the individual patients medical history and eligibility criteria.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Expanded Access
Official Title:
Expanded Access for KHK2455
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Kyowa Kirin, Inc.
- University of New Mexico Cancer Center
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Kyowa Kirin, Inc.
ClinicalTrials.gov Identifier:
NCT04321694
Other Study ID Numbers:
- Expanded Access for KHK2455
First Posted:
Mar 25, 2020
Last Update Posted:
Aug 10, 2021
Last Verified:
Mar 1, 2020